Japan represents a significant hub for neurodegenerative disease research and drug development, with major pharmaceutical companies, innovative biotech startups, and world-class academic research institutions contributing to advances in Alzheimer's disease, Parkinson's disease, and related conditions. The country's strength in induced pluripotent stem cell (iPSC) technology, regenerative medicine, and precision medicine approaches has made it a global leader in neurodegeneration research. Japan's regulatory environment supports rapid clinical translation, and companies like Eisai have demonstrated this through the accelerated approval pathway for lecanemab in both the US and Japan["@lecanemab"].
This page catalogs Japanese companies actively developing therapies for neurodegeneration, from large multinational pharmaceutical companies like Eisai and Takeda to innovative startup biotechs and academic spin-outs emerging from institutions like Kyoto University, the University of Tokyo, and RIKEN.
Eisai is a leading Japanese pharmaceutical company with a strong focus on neurology and has become globally recognized for its Alzheimer's disease research. The company co-developed lecanemab (Leqembi) with Biogen, an amyloid-beta targeting antibody approved for early Alzheimer's disease. Lecanemab represents the first disease-modifying therapy to demonstrate meaningful slowing of cognitive decline in a pivotal Phase 3 trial (Clarity AD), showing a 27% reduction in clinical decline at 18 months[@lecanemab]. Eisai has also developed lemborexant for sleep-wake disorders, addressing the circadian dysfunction commonly seen in Alzheimer's and Parkinson's disease patients.
Eisai's neuroscience pipeline includes tau aggregation inhibitors, amyloid-beta antibodies, and neuroinflammation modulators. The company maintains a robust partnership network with academic institutions including RIKEN and Kyoto University, leveraging Japan's strengths in iPSC technology for drug discovery[@eisai_annual].
Takeda is Japan's largest pharmaceutical company and has strategically rebuilt its neuroscience pipeline after divesting its legacy CNS portfolio. The company has pursued an aggressive acquisition strategy to strengthen its neurology capabilities, acquiring companies with innovative mechanisms for neurodegenerative diseases. Takeda's neuroscience focus areas include tau immunotherapy collaborations, neuroprotective agents, and novel approaches targeting protein aggregation in both Alzheimer's and Parkinson's disease[@takeda_neur].
Daiichi Sankyo has a significant CNS pipeline focusing on novel mechanisms for neurodegenerative diseases. The company is developing tau-targeted therapies and maintains active collaborations with academic institutions in Japan for neuroscience research. Daiichi Sankyo's drug discovery platform emphasizes precision medicine approaches for patient stratification.
Astellas focuses on innovative medicine discovery in multiple therapeutic areas including urology, oncology, and immunology. The company has active research in neurodegenerative diseases with programs targeting protein aggregation and neuroinflammation. Astellas has invested significantly in gene therapy and next-generation modalities for neurological diseases.
A member of the Mitsubishi UFJ Financial Group, Mitsubishi Tanabe has a heritage in CNS drug development. The company has developed treatments for neurological disorders and continues to invest in research for neurodegenerative diseases, particularly in Parkinson's disease where it has market presence with existing therapies.
Sumitomo Pharma focuses on psychiatry, neurology, and oncology. The company has developed treatments for depression and schizophrenia and is expanding into neurodegenerative disease research with novel small molecule approaches.
Otsuka is known for its innovative approaches in psychiatry and neurology, having developed treatments for schizophrenia and bipolar disorder. The company is exploring novel mechanisms for neurodegenerative diseases, particularly focusing on neuroinflammation and protein aggregation pathways.
Chugai, a member of the Roche group, bridges Japanese innovation with global pharmaceutical capabilities. The company develops biologics and novel antibodies for neurodegenerative diseases, leveraging Chugai's proprietary antibody engineering technologies. Chugai has active programs in Alzheimer's disease targeting amyloid-beta and tau pathology.
Kyowa Kirin focuses on specialty pharmaceuticals with strength in oncology, immunology, and nephrology. The company has expanded into neurological diseases with programs targeting neuroinflammatory pathways and pain mechanisms relevant to neurodegenerative conditions.
Tree Pharmaceutical is an Osaka-based biotechnology company dedicated to developing novel therapeutics for neurodegenerative diseases. The company focuses on amyloid-beta and alpha-synuclein targeting approaches, leveraging Japan's strong academic research base to advance novel drug candidates through clinical development.
Accerise is a Tokyo-based drug discovery company utilizing structure-based design and computational approaches to develop therapeutics for neurodegenerative diseases. The company's proprietary platform enables rapid optimization of drug candidates targeting previously undruggable proteins involved in neurodegeneration.
Kinevo is a Tokyo-based biotechnology company focused on developing therapeutics targeting mitochondrial dysfunction in neurodegenerative diseases. Mitochondrial dysfunction is increasingly recognized as a central mechanism in both Alzheimer's and Parkinson's disease pathogenesis, making this a high-value target area.
CureApp is a Tokyo-based company developing digital therapeutics (DTx) for Alzheimer's disease and Parkinson's disease. The company takes a software-as-medical-device approach, developing smartphone-based interventions that can modify disease progression through cognitive training, behavioral modification, and remote monitoring.
Peptidream is a Tokyo-based company with a proprietary peptide discovery platform that generates constrained cyclic peptides with drug-like properties. The company's technology enables development of peptides that can target protein-protein interactions that are difficult to address with small molecules, making it valuable for neurodegenerative disease targets.
Helios is a Japanese biotech company developing innovative therapies for neurodegenerative diseases through small molecule drugs and regenerative medicine approaches. The company has a pipeline targeting Alzheimer's disease, Parkinson's disease, and ALS, including tau aggregation inhibitors and alpha-synuclein modulators.
RNP Inc. specializes in RNA-based therapeutics and diagnostics for neurodegenerative diseases. The company is developing antisense oligonucleotides (ASO) and RNAi therapeutics targeting genetic risk factors and disease-driving proteins in Alzheimer's and Parkinson's disease.
Kinexx is a Japanese biotech company focused on developing therapies for protein aggregation diseases, particularly neurodegenerative disorders. The company targets abnormal protein folding and aggregation that characterizes diseases like Alzheimer's and Parkinson's.
Nobelpharma focuses on orphan diseases and has developed drugs for rare conditions. The company has interest in neurological orphan diseases and collaborates with academic institutions on neurodegenerative research.
ID Pharma is a Japanese biotech specializing in gene therapy and viral vector technology. The company provides contract manufacturing services and develops gene therapies for various diseases, including neurological conditions.
MedRx develops medical devices and diagnostic tools for neurological diseases, in addition to therapeutic programs. The company focuses on early diagnosis and monitoring of neurodegenerative conditions.
ReproCELL is a Japanese biotechnology company specializing in induced pluripotent stem cell (iPSC) technology and regenerative medicine. Founded in 2013 as a spin-out from Kyoto University's CiRA, ReproCELL provides iPSC-derived products and services for drug discovery, with disease models for Alzheimer's disease and Parkinson's disease.
Renascience is a Tokyo-based company developing iPSC-based cell therapies and gene therapies for neurodegenerative diseases. The company is developing disease-modifying therapies that address the underlying pathology of Alzheimer's and Parkinson's disease rather than just managing symptoms.
SanBio is a Tokyo-based regenerative medicine company developing cell therapy products for neurological disorders. The company's lead product candidate SB623 is a cell therapy product being evaluated for stroke recovery and traumatic brain injury.
Healios is a Tokyo-based iPSC company developing cell therapies for various diseases including ischemic stroke. The company leverages Japan's leadership in iPSC technology to develop allogeneic cell therapies.
Sosei Group is a Tokyo-based GPCR-focused drug discovery company, acquired by Novo Nordisk in 2023. The company developed a proprietary structure-based drug design platform (StaR technology) that enables optimization of GPCR-targeted therapeutics.
Kyorin Pharmaceutical is a Tokyo-based company with focus on CNS diseases and immunology. The company has a pipeline of neurology therapeutics under development and maintains partnerships with academic researchers in Japan.
Kissei Pharmaceutical is a Matsumoto-based company developing treatments for neurological disorders. The company has research programs focused on novel mechanisms for neurodegenerative diseases.
Nippon Shinyaku is a Kyoto-based company focused on rare diseases and oligonucleotide therapeutics. The company's expertise in oligonucleotide chemistry positions it for nucleic acid-based therapies for neurodegenerative diseases.
RIBOMIC is a Tokyo-based RNA therapeutics company specializing in RNA aptamer technology for ocular and CNS disorders. RNA aptamers offer an alternative to antibody therapeutics with potentially better tissue penetration and manufacturing advantages.
NanoCarrier is a Tokyo-based drug delivery company using polymeric micelle technology for targeted therapeutics. The company's delivery platform can improve brain penetration of neuroprotective compounds.
Daiwa Sangyo is a Japanese manufacturer of pharmaceutical intermediates for CNS drugs and provides contract manufacturing services. The company supports both Japanese and international pharmaceutical companies with manufacturing capabilities.
Kaken Pharmaceutical is a Tokyo-based pharmaceutical company with focus on CNS disorders and neuropathic pain treatments. The company has research programs addressing pain and neurological symptoms associated with neurodegenerative diseases.
[Krasue Inc.](/institutions/krasue-inc) (from Kyoto University)
RIKEN is Japan's flagship research institute with a world-renowned brain science center. Researchers at RIKEN have made significant contributions to understanding amyloid-beta toxicity, tau pathology, and alpha-synuclein in neurodegenerative diseases[@riken_brain]. The center houses state-of-the-art imaging facilities, iPSC research capabilities, and maintains active collaborations with pharmaceutical companies for translational research.
NCNP is Japan's only national research hospital specializing in neurology and psychiatry. The institute conducts clinical research on Alzheimer's disease, Parkinson's disease, and other neurodegenerative conditions, and maintains patient registries and biobanks that support drug discovery efforts.
This institute conducts fundamental and translational research on neurodegenerative diseases, with particular strength in Parkinson's disease research and movement disorders.
Japanese companies, particularly Eisai, have led global efforts in amyloid-beta antibody development. Lecanemab represents a major breakthrough in disease modification for early Alzheimer's disease, demonstrating that removing amyloid-beta from the brain can slow cognitive decline[@lecanemab]. Japanese researchers at RIKEN have contributed fundamental discoveries about amyloid-beta structure and toxicity mechanisms that informed these therapeutic approaches.
Multiple Japanese institutions and companies are pursuing tau-targeted therapies:
Japanese biotech companies are developing small molecules targeting abnormal protein aggregation in AD and PD, addressing both amyloid-beta and alpha-synuclein pathologies. The country's strength in structural biology and cryo-EM has accelerated target identification and drug design.
Research into neuroinflammation as a therapeutic target is active in Japan, with companies developing anti-inflammatory approaches for neurodegenerative diseases. This includes microglia modulation, NLRP3 inflammasome inhibitors, and cytokine-targeting strategies.
Japanese companies like ID Pharma are advancing gene therapy approaches for neurological diseases, including potential applications in neurodegenerative conditions. AAV vector development and gene editing technologies are active research areas.
Japan's leadership in iPSC technology supports cell replacement therapies for Parkinson's disease and other neurodegenerative conditions. Companies like Renascience, SanBio, and Healios are developing cell-based approaches that could restore lost neuronal populations.
Japan offers a favorable environment for clinical trials in neurodegenerative diseases, with:
Japan has established regional innovation hubs supporting biotech development:
Japanese universities have become increasingly active in spin-out company formation, with technology transfer offices (TLOs) supporting commercialization of academic research in neurodegeneration.